Maravai LifeSciences (NASDAQ:MRVI) Releases Earnings Results, Misses Estimates By $0.08 EPS

Maravai LifeSciences (NASDAQ:MRVI) announced its quarterly earnings results on Monday. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.08), Zacks reports. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. Maravai LifeSciences updated its FY 2025 guidance to EPS.

Maravai LifeSciences Trading Up 7.1%

Maravai LifeSciences stock traded up $0.14 during trading hours on Monday, hitting $2.12. The stock had a trading volume of 3,069,570 shares, compared to its average volume of 2,335,650. The stock has a market cap of $539.19 million, a price-to-earnings ratio of -1.29 and a beta of 0.19. The business’s 50 day simple moving average is $2.17 and its 200-day simple moving average is $4.19. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. Maravai LifeSciences has a one year low of $1.67 and a one year high of $11.56.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Morgan Stanley decreased their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 25th. Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a research report on Friday, March 21st. UBS Group dropped their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research note on Friday, March 21st. Baird R W lowered Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Bank of America cut their price target on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Maravai LifeSciences has an average rating of “Hold” and a consensus price target of $6.34.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.